Russia’s Sputnik V Vaccine 91.6% Effective in Late-Stage Trial | Read Less - Know All

Russia’s Sputnik V Vaccine 91.6% Effective in Late-Stage Trial

Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing COVID-19, according to peer-reviewed results from its late-stage clinical trial published in The Lancent international medical journal on Tuesday. The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.


@ReadLessKnowAll